AOD 9604 - Research Profile & Reviews

Research Overview

AOD 9604 is a synthetic peptide representing a modified fragment of the C-terminus of human growth hormone (amino acids 177-191) with an added tyrosine at the N-terminus. Developed by Professor Frank Ng at Monash University in Australia, it was designed to isolate the fat-reducing properties of growth hormone while eliminating its growth-promoting and potentially diabetogenic effects.

The peptide stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) through a mechanism distinct from the GH receptor. AOD 9604 interacts with the beta-3 adrenergic receptor pathway and activates calcium-dependent intracellular signaling to promote fat metabolism. Importantly, it does not affect blood sugar levels or cause cellular proliferation, addressing key safety concerns associated with GH therapy.

Clinical research including Phase II trials demonstrated that AOD 9604 produced statistically significant weight loss in obese subjects over 12 weeks of treatment. Studies showed preferential reduction of abdominal fat while preserving lean muscle mass. The peptide received Generally Recognized as Safe (GRAS) status from the FDA for use as a food supplement in 2010. Research has also explored its potential benefits for osteoarthritis and cartilage repair, with studies showing stimulation of proteoglycan and collagen synthesis in cartilage tissue.

Documented Research Effects

Fat Loss Joint Health Energy

Dosage & Protocol

Typical Dose Range

250 – 500

mcg per dose

Frequency

1x daily (morning, fasted)

Cycle Length

12-20 weeks

Common Vial Sizes

5 10

Calculate exact draw volumes and reconstitution steps.

Use Calculator

Dosage information is for research reference only. Always follow established research protocols. Not medical advice.

Storage & Handling

Lyophilized Powder

Temperature -20°C

Shelf Life 2+ years

Reconstituted Solution

Temperature 2-8°C

Shelf Life 4-6 weeks

Frequently Asked Questions

AOD 9604 is a modified fragment (amino acids 177-191) of the human growth hormone molecule. It mimics the lipolytic (fat-burning) effects of GH by stimulating the beta-3 adrenergic receptor in adipose tissue, promoting the breakdown of stored fat (lipolysis) and inhibiting lipogenesis (new fat formation). Importantly, it does this without the diabetogenic effects of full-length GH, meaning it does not negatively impact blood sugar or insulin sensitivity.

AOD 9604 should be administered in the morning on an empty stomach, at least 30 minutes before eating. The fasted state is important because insulin can interfere with its fat-burning mechanism. Some protocols include a second dose before bed on an empty stomach. Avoid eating for at least 20-30 minutes after injection to maintain low insulin levels during the peptide active window.

No, AOD 9604 does not increase IGF-1 or overall growth hormone levels. It is specifically the fat-metabolizing fragment of HGH and does not retain the growth-promoting or diabetogenic properties of full-length growth hormone. This makes it a targeted approach to fat loss without the broader hormonal changes associated with GH therapy or GH secretagogues.

Most users begin to notice changes in body composition after 4-6 weeks of consistent use, with more significant results appearing over 12-20 weeks. AOD 9604 works best when combined with a caloric deficit and regular exercise. It is not a replacement for diet and exercise but rather a tool that enhances fat metabolism. Results vary based on starting body composition, diet, and activity level.

Community Reviews

All 89 reviews →

No Reviews Yet

Community reviews for AOD 9604 are being collected. Check back soon.